Abivax Celebrates Successful Financing with $747.5 Million Offering
Abivax, a clinical-stage biotechnology firm, is excited to announce the closing of its recently completed public offering, securing approximately $747.5 million. This funding comes at a crucial time as the company focuses on developing innovative therapies aimed at regulating the immune response in patients facing chronic inflammatory diseases.
Financial Details of the Offering
The public offering comprised 11,679,400 American Depositary Shares (ADSs), with each representing an ordinary share of Abivax. Notably, this offering saw the full exercise of the underwriters' option to purchase additional ADSs, further enhancing the proceeds. The gross amount raised, before the deduction of offering expenses and underwriting commissions, is estimated at €637.5 million, or around $747.5 million. The net proceeds expected amount to roughly $700.3 million, post-deductions.
Impact on Operations and Future Plans
Abivax's management believes this significant influx of capital will enable the company to sustain its operations and clinical development plans well into the fourth quarter of 2027. More specifically, the anticipated timeline allows Abivax to progress through the next twelve months, following the projected New Drug Application (NDA) submission for their promising treatment of Ulcerative Colitis, assuming favorable outcomes from ongoing clinical trials.
Strategic Support and Underwriters
Leading the offering were prominent firms including Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, which acted as joint bookrunning managers. LifeSci Capital took the role of lead manager, with additional support from BTIG and Van Lanschot Kempen as co-managers. Their combined expertise is expected to facilitate a successful transition into the expected phases following this capital raise.
Company's Vision and Commitment
Based in France and the United States, Abivax is committed to harnessing natural bodily processes to develop therapeutic strategies that alleviate chronic inflammatory diseases. Their lead candidate, obefazimod (ABX464), is currently in Phase 3 trials, specifically targeting moderately to severely active ulcerative colitis. The ongoing research and development efforts remain pivotal in Abivax's mission to produce effective treatments that enhance patients' quality of life.
Contact Information for Further Inquiries
For investors looking for more information about the offering or the company's future endeavors, Abivax has made a point to retain open lines of communication. Abivax Investor Relations can be reached through Patrick Malloy at +1 847 987 4878 or via email at patrick.malloy@abivax.com.
Frequently Asked Questions
What was the total amount raised in the public offering?
Abivax successfully raised approximately $747.5 million in its latest public offering.
How many American Depositary Shares were offered?
The offering included a total of 11,679,400 American Depositary Shares.
What are the intended uses for the funds raised?
The funds will primarily support ongoing operations and clinical developments as Abivax approaches its NDA submission.
Which firms managed the public offering?
Leerink Partners, Piper Sandler & Co., and Guggenheim Securities acted as the main managers for the offering.
What is Abivax's lead drug candidate?
Abivax's lead candidate is obefazimod (ABX464), aimed at treating ulcerative colitis and currently in Phase 3 trials.
